CDH3

(redirected from P-cadherin)

CDH3

A gene on chromosome 16q22.1 that encodes a calcium-dependent cell–cell adhesion glycoprotein (cadherin), which is involved in regulating cell–cell adhesions, mobility and proliferation of epithelial cells. CDH3 is also a retired HUGO symbol for what is now designated CDH15, see there.

Molecular pathology
Loss of heterozygosity mutations of CDH3 occur in breast and prostate cancer; aberrant expression of cadherin 3 occurs in cervical adenocarcinomas. CDH3 mutation causes congenital hypotrichosis with juvenile macular dystrophy and ectodermal dysplasia with ectrodactyly and macular dystrophy.
References in periodicals archive ?
Tumors with positive cells in a percentage >10% was considered positive for e-cadherin, p-cadherin, and bcatenin.
All CDH genes (n = 27) screened in this study include CDH1 (E-cadherin), CDH2 (N-cadherin), CDH3 (P-cadherin), CDH4 (R-cadherin), CDH5 (VE-cadherin), CDH6 (K-cadherin), CDH7 (cadherin 7), CDH8 (cadherin 8), CDH9 (T1-cadherin), CDH10 (T2-cadherin), CDH11 (OB-cadherin), CDH12 (N-cadherin 2), CDH13 (H-cadherin), CDH15 (M-cadherin), CDH16 (KSP-cadherin), CDH17 (LI-cadherin), CDH18 (cadherin 18), CDH20 (cadherin 20), PCDHGA12 (CDH21), CDH22 CDH23 CDH24 DCHS1 (CDH19, or CDH25), CDH26 DCHS2 (CDH27), CDHR3 (CDH28), and CDHR4 (CDH29).
Williams et al, (13) found upregulation of P-cadherin expression in severe dysplasia and reduced expression of the E-cadherin and/or catenins in carcinoma in situ and infiltrating tumors.
P-cadherin is a protein that is over-expressed in many common types of cancer, including lung, pancreatic and colon cancers, and is implicated in tumor growth and cancer disease progression.
FF-21101 uses antibodies that target P-cadherin, which is over-expressed on the surface of solid cancer cells, and accumulated in lung cancer cells, pancreatic cancer cells, etc.
The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma.
Other MEC markers, such as SMA, p-cadherin, Wilms tumor 1 (WT1), S100, and high-molecular-weight cytokeratin (HMWCK) or basal-type cytokeratin (CK) (CK5/6, CK14, CK17, CK903) are less commonly used because of marked cross-reactivity with myofibroblasts and vascular SMA, (4-9,19,20) frequent reactivity in tumor cells (HMWCK or basal-type CK, S100, p-cadherin), (4-8,19,32-34) or low sensitivity (WT1 and S100).
The expression of P-cadherin is restricted only to basal or lower layers of epithelia, including prostate and skin and also to breast myoepithelial cells (MECs).
Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.